Hallucinations
AI-driven app shows ‘benefits across the board’ for managing cancer symptoms through diet
CHICAGO — Most individuals with cancer who used an AI-based nutritional platform reported the application helped them regulate their diets and improved their quality of life, according to study results presented at ASCO Annual Meeting.
FDA grants breakthrough device designation to digital therapeutic for schizophrenia
The FDA has granted breakthrough device designation for CT-155, an investigational prescription digital therapeutic co-developed by Click Therapeutics and Boehringer Ingelheim to treat negative symptoms of schizophrenia.
Phase 2 study of Alzheimer’s disease psychosis therapy initiated
A phase 2 clinical trial has been initiated to evaluate the safety and efficacy of an inverse agonist for hallucinations and delusions associated with Alzheimer’s disease psychosis, according to the manufacturer.
VIDEO: Ask patients with brain injury about visual hallucinations
WASHINGTON — Patients who have experienced brain injuries that are multiple, bilateral, severe or diffuse may present with undiagnosed visual hallucinations, according to a poster presented at Optometry’s Meeting.
More than 5.5 million American adults use hallucinogens
More than 5.5 million American adults aged 18 years and older, including more than 3 million aged 26 years and older, use hallucinogens, researchers estimated in Addiction.
VIDEO: Functional vision loss has connection to hallucinations, delusions
AUSTIN, Texas — In this Healio Video Perspective from the North American Neuro-Ophthalmology Society meeting, Victoria Pelak, MD, discusses functional vision loss and how it connects to people with visual hallucinations and delusions.